File downloaded on 2026-11-08
Source URL: https://medicines.health.europa.eu/veterinary/en/600000004636

Strangvac (--) - Suspension for injection

Authorised

- Streptococcus equi subsp. equi, recombinant protein CCE
- Streptococcus equi subsp. equi, recombinant protein Eq85
- Streptococcus equi subsp. equi, recombinant protein IdeE

Product identification

Medicine name:
Strangvac (--) - Suspension for injection

Active substance:
Streptococcus equi subsp. equi, recombinant protein CCE
Streptococcus equi subsp. equi, recombinant protein Eq85
Streptococcus equi subsp. equi, recombinant protein IdeE

Target species:
Horse

Route of administration:
Intramuscular use

Product details

Active substance and strength:
Streptococcus equi subsp. equi, recombinant protein CCE

Presentation_strength:≥111.8 µg Reference:Hse Index:0
Streptococcus equi subsp. equi, recombinant protein Eq85
Presentation_strength:≥44.6 µg Reference:Hse Index:1
Streptococcus equi subsp. equi, recombinant protein IdeE
Presentation_strength:≥34.6 µg Reference:Hse Index:2

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Horse**
  - Not applicable. 0 day Zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI05AB01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:
Packaging:Vial (glass), Package_size:8 vials, Content:2 ml

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervacc AB

Marketing authorisation date:
16/08/2021

Manufacturing sites for batch release:
3 P Biopharmaceuticals S.L.

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
16/08/2021

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)
Published on: 6/10/2026
Download

ema-puar-strangvac-epar-public-assessment-report-en.pdf